MedTrace Logo

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

NCT02175602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2015-02-10

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of Daclatasvir, Asunaprevir, and BMS-791325 on the pharmacokinetics of selective serotonin reuptake inhibitors.

Conditions

  • Hepatitis C Infection

Interventions

DRUG

Escitalopram

10 milligrams administered each morning

DRUG

Sertraline

50 milligrams administered each morning

DRUG

DCV 3DAA FDC

Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily

DRUG

BMS-791325

75 milligrams single-agent film coated oral tablet administered twice daily

Sponsors & Collaborators

Principal Investigators

  • Ikenna Ogbaa, MD · PPD Development, LP

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175602 on ClinicalTrials.gov